New Medical Policy: General Inflammation Testing
New Medical Policy: Alcohol Injections for the Treatment of Peripheral Neuromas
Morton neuroma is a common and painful compression neuropathy of the dorsal foot that is usually treated with conservative measures, surgery, or minimally invasive procedures. Alcohol injection, a minimally invasive alternative to surgery, causes chemical neurolysis through dehydration, necrosis, and precipitation of the treated area, then ultimately destroys the lesion after multiple injections.
Effective November 1, 2018, BlueCross® BlueShield® of South Carolina and BlueChoice® HealthPlan will implement a new medical policy addressing the use of alcohol injection and why it is considered investigational for the treatment of Morton neuroma and all other diagnoses. The policy, CAM 20197 – Alcohol Injections for the Treatment of Peripheral Neuromas, has been published on the Medical Policies pages of the BlueCross and BlueChoice® websites.
The investigational procedure and diagnosis codes listed in the coding section of the medical policy are below. These codes are included in the medical policy as a general reference tool and may not be all-inclusive:
|64632||Destruction by neurolytic agent, plantar common digital nerve|
|G57.60 – G57.62||Lesion of plantar nerve code range (include Morton metarsalgia|
For complete information about CAM 20197, visit our Medical Policies page. Please remember medical necessity is not a guarantee of payment. Payment is subject to the member’s plan coverage, to include prior authorization requirements and benefits, at the time the service is performed. You may contact Provider Education by using the Provider Education Contact Form or by calling 803-264-4730 with additional questions.
BlueChoice® HealthPlan of South Carolina is an independent licensee of the Blue Cross and Blue Shield Association.